123I-FP-CIT SPET striatal uptake in parkinsonian patients with the α-synuclein (G209A) mutation

Hellenic Journal of Nuclear Medicine

Volumn 11, Issue 3, 2008, Pages 157-159

  Bostantjopoulou, Sevasti ^a,c   Katsarou, Zoe ^a   Gerasimou, George ^a   Costa, Durval C ^b   Gotzamani Psarrakou, Anna ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c NONE   (Greece)

Author keywords

synuclein; Dopamine transporter; Familial parkinsonism; I 123 FP CIT (DaTSCAN); SPET

Indexed keywords

ADENOSINE; ALANINE; ALPHA SYNUCLEIN; GUANOSINE; IOFLUPANE; IOFLUPANE I 123; LEVODOPA; PRAMIPEXOLE; RADIOISOTOPE; RADIOLIGAND; ROPINIROLE; THREONINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BOLUS INJECTION; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DIFFERENTIAL DIAGNOSIS; DRUG UPTAKE; FAMILIAL DISEASE; GENE MUTATION; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; MONOTHERAPY; NERVE CELL DEGENERATION; PARKINSON DISEASE; PUTAMEN; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UNIFIED PARKINSON DISEASE RATING SCALE;

ADULT; ALPHA-SYNUCLEIN; CORPUS STRIATUM; HUMANS; IODINE RADIOISOTOPES; MIDDLE AGED; MUTATION; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TROPANES;

EID: 60849100528     PISSN: 11081430     EISSN: 17905427     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Polymeropoulos MH, Lavedan C, Leroy E et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-2047.
2. Bostantjopoulou S, Katsarou Z, Papadimitriou A et al. Clinical features of parkinsonian patients with the a-synuclein (G209A) mutation. Mov Disord 2001; 16: 1007-1013.
3. Papapetropoulos S, Paschalis C, Athanassiadou I et al. Clinical phenotype in patients with α-synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease. J Neurol Neurosurg Psychiatry 2001; 70: 662-665.
4. Spira PJ, Sharpe DM, Halliday G et al. Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr α-synuclein mutation. Ann Neurol 2001; 49: 313-319.
5. Kaufman MJ, Madras B. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse 1991; 9: 43-49.
6. Piccini P. Dopamine transporter: basic aspects and neuroimaging. Mov Disord 2003; 18 (Suppl. 7): S3-S8.
7. Scherfler C, Schwarz J, Antonini A et al. The role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord 2007; 22: 1229-1238.
8. Fahn S, Elton R, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, editors. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Healthcare Information; 1987: 153-163 & 293-304.
9. 123I] b-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995; 38: 589-598.
10. Løkkegaard A, Werdelin L, Friberg L. Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. Eur J Nucl Med 2002; 29: 1623-1629.
11. 123I)β-CIT and single-photon emission computed tomographic imaging versus clinical evaluation in parkinsonian syndrome. Arch Neurol 2004; 61: 1224-1229.
12. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labeling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62: 133-140.
13. Parkinson Study Group. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology 2000; 55: 1540-1547.
14. Samii A, Markopoulou K, Wszolek Z et al. PET studies of parkinsonism associated with mutation in the α-synuclein gene. Neurology 1999; 53: 2097-2102.
15. Ahn T, Kim S, Kim J et al. α-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology 2008; 70: 43-49.
16. Scherfler C, Khan N, Pavese N et al. Striatal and cortical pre- and post-synaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain 2004; 127: 1332-1342.
17. 18F-dopa study. Ann Neurol 2002; 52: 849-853.
18. Weng Y, Wu Chou Y, Wu W et al. PINK1 mutation in Taiwanese early-onset parkinsonism: clinical, genetic, and dopamine transporter studies. J Neurol 2007; 254: 1347-1355.
19. Adams J, van Netten H, Schulzer M et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005; 128: 2777-2785.
20. 123I-IBZM SPECT study. Mov Disord 2004; 19: 1320-1325.
21. Yen T, Tzen K, Chen M et al. Dopamine transporter concentration is reduced in asymptomatic Machado-Joseph disease gene carriers. J Nucl Med 2002; 43: 153-159.
22. Golbe L, Di Iorio G, Bonavita V et al. A large kindred with autosomal dominant Parkinson's disease. Ann Neurol 1990; 27: 276-282.